web analytics
4.7 C
Munich
Tuesday, November 29, 2022

Stock in Focus: NuvilexInc (OTCMKTS:NVLX)

NuvilexInc (OTCMKTS:NVLX) is moving up fast on huge volume as pot stocks take center stage and heat up the bb’s. NVLX is a stock with a history of big moves; everyone remembers the EPIC run that NVLX made from $0.10 to over $0.60 a share earlier this year.

Nuvilex Inc (OTCMKTS:NVLX) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon their unique, proprietary and patented cellulose-based live cell encapsulation technology known as Cell-in-a-Box®.

The live-cell encapsulation technology employed by Nuvilex is a way to enclose living cells in protective “cocoons” about the size of the head of a pin. Each capsule can enclose approximately 10,000 cells and the technology is considered a “platform” upon which treatments can be developed.

Dr.Mark Rabe, chairman of the advisory board of Nuvilex subsidiary, Medical Marijuana Sciences (MMS) summed it up perfectly when he said ”The live cell encapsulation platform employed by Nuvilex is a unique patented technology on which treatments can be developed for deadly and debilitating diseases such as cancer and diabetes. The technology has shown to be successful in the treatment of pancreatic cancer in initial clinical trials using the conventional chemotherapy drug ifosphamide. ”

To get a sense of just how valuable Nuvilex technology could be, consider a recent report published by U.S. based market research company, Transparency Market Research “ the global diabetes devices and drugs market was valued at USD 54.04 billion in 2012 and is estimated to reach a market worth of USD 83.0 billion in 2019 growing at a CAGR of 5.9% from 2013 to 2019.

Many investors in the Company view Nuvilex Cell-in-a-Box® cell encapsulation technology as THE future of diabetes treatment and suggest the Company is a prime buy out candidate from a major such as Bayer who may be closely watching NVLX.

To Find out the inside Scoop on NVLX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

NVLX has benefited from the Marijuana connection; the sector, although it has cooled significantly has been seriously hot with weed legalized in Alaska, Oregon and Washington DC, Colorado and Washington state.

Nuvilex subsidiary, Medical Marijuana Sciences, Inc., is exploring the benefits of using the Cell-in-a-Box(TM) technology in optimizing the anticancer effectiveness of cannabinoids while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments.

NVLX landed a leading figure in the medical marijuana field in Dr. Mark L. Rabe who was appointed as the Chairman of the Scientific Advisory Board of Medical Marijuana Sciences (MMS).

In fact Nuvilex has been very successful in attracting top talent to the Company including their COO Dr. Crabtree who used to work at Bristol Meyers and successfully managed the project that achieved FDA approval for Taxol. Another huge asset is their Chief Scientific Officer ; Dr. Robert F. Ryan an expert in helping small companies in bringing their products to market through the rigorous FDA approval process.

We have a Monster Pick Coming. Subscribe Right Now!

Nuvilex has made some huge steps recently towards accelerated FDA approval for its pancreatic cancer treatment using Phase 2b data that outperformed Eli Lilly’s Gemzar in prior trials. December promises to be an exciting month for Nuvilex with a number of big things in the works. The stock needs to find a bottom and show some support, then good things can happen.

Investors seem to love this stock and see it as a long term investment. They believe the Cell-In-The-Box technology beats the current Gold Standard on The market, and we are talking about a market worth billions. Nuvilex has made some huge steps recently towards accelerated FDA approval for its pancreatic cancer treatment using Phase 2b data that outperformed Eli Lilly’s Gemzar in prior trials. December promises to be an exciting month for Nuvilex with a number of big things in the works. The stock needs to find a bottom and show some support, then good things can happen.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in NVLX either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.